Increased cumulative and intensity dosing have improved complete response (CR) rates and event-free survival (EFS) in HL. 9, 10 This relationship with the response warranted dose escalation from standard cyclophosphamide, vincristine, procarbazine, and prednisone [COPP]/ABVD to bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP) at baseline (BEACOPP baseline ) and escalated BEACOPP (BEACOPP escalated ; HD9 trial).
11-13 BEACOPP escalated compared with BEACOPP baseline provided fewer early progressions and higher 3-year freedom from treatment failure (FFTF) and EFS at 40 months (89% v 79%) and 70% with standard COPP/ABVD (P , .05 each comparison). This higher FFTF translated into a higher overall survival (OS): 92% for BEACOPP escalated and 91% for BEACOPP baseline versus 86% for COPP/ABVD. Deaths were 32 of 463 versus 41 of 457 versus 46 of 263, respectively.
14 However, no FFTF advantage was observed in patients older than age 60 years. Immediate toxicity was severe: grade 3 to 4 anemia occurred in 25% of the cycles and 69% of the patients. More occurrences of therapy-related acute myeloid leukemia and myelodysplastic syndromes were observed in the BEACOPP escalated arm (1.8% [SE, 0.8%] after 3 years).
The HD12 trial confirmed the HD9 results: it compared eight cycles of BEACOPP escalated with BEACOPP 4+4 (with or without involved field radiotherapy), which was meant to reduce late hematologic and gonadal toxicity in young patients while maintaining disease control, mainly through a 25% reduction of the cumulative dose of etoposide (4.8 g/m 2 reduced to 3.6 g/m 2 ).
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This reinforced the hypothesis that a dose increment was important primarily during the first part of the treatment. 16 Indeed, in accordance with the effective dose model, similar results were observed in the HD12 trial: FFTF was 86.4% and 84.8% (difference, -1.6%; 95% CI, -5.2% to 1.9%), progression-free survival (PFS) was 87.5% and 85% (difference, -2.5%; 95% CI, -6% to 1%), and 5-year OS was 92% versus 90.3% (difference, -1.7%; 95% CI, -4.6% to 1.1%), respectively. 13, 15 Similarly, eight cycles of BEACOPP escalated was tested against six cycles of BEACOPP escalated in the HD15 trial: the 5-year FFTF rates were 84.4% for eight cycles of BEACOPP escalated versus 89.3% for six cycles of BEACOPP escalated (97.5% CI, 0.5% to 9.3% for difference), thus promoting the standard of care. OS was 91.9% versus 95.3%, respectively (97.5% CI, 0.36 to 0.98). 17 The cumulative drug doses in the BEACOPP 4+4 regimen and in six cycles of BEACOPP escalated are almost identical, a relevant criterion in the effective dose model (doxorubicin, 240 v 210 mg/m 2 ; cyclophosphamide, 7,600 v 7,500 mg/m 2 ; etoposide, 3,600 v 3,600 mg/m 2 ; and procarbazine, 560 v 420 mg/m 2 , respectively).
The contribution of radiotherapy was unclear in the HD9 trial; it was marginal and restricted to the 10% of the patients with residual disease of 2.5 cm or more who were still positive by positron emission tomography after chemotherapy in the HD12 trial.
14,15,17 Conversely, a large randomized trial showed that consolidation radiotherapy was detrimental for OS in CR and CR unconfirmed (CRu) patients after chemotherapy. 18 First-line irradiation was not allowed in the EORTC 20012 Intergroup protocol.
Considering that standard dose regimens are suboptimal in poor-prognosis advanced-stage HL, we selected the patients with International Prognostic Score (IPS) $ 3 as the most likely to benefit from increased chemotherapy dosing. 19 We aimed to clarify whether BEACOPP escalated, provides a better EFS and leads to a longer OS than ABVD, especially because COPP/ABVD was not a standard therapy regimen.
16,20-23 Meanwhile, two trials compared ABVD and BEACOPP 4+4 and failed to show a survival difference.
24,25 These randomized trials contradict the results of a recent and contested German Hodgkin Study Group meta-analysis that addressed the effect of initial treatment strategy on the survival of patients with advanced-stage HL, which increased interest in the EORTC 20012 Intergroup study, the largest one to target patients with high-risk stage III or IV HL. 26 ,27
PATIENTS AND METHODS
The European Organisation for Research and Treatment of Cancer Lymphoma Group led this phase III intergroup trial, in collaboration with the Lymphoma Study Association, Groupe d'Etude des Lymphomes de l'Adulte, the Australasian Leukaemia and Lymphoma Group, the National Cancer Research Institute Lymphoma Group, Grup per l'Estudi dels Limfomes de Catalunya i Balears, the National Cancer Institute of Canada Clinical Trials Group, and the Nordic Lymphoma Group.
Patients
Inclusion criteria included untreated histologic classic HL, age 16 to 60 years, clinical stage III or IV, at least one bidimensionally measurable target lesion, performance status (PS) of 0 to 2, IPS $ 3, and no other malignancies except basal cell skin and in situ uterine cervix carcinomas. Exclusion criteria included no measurable disease; fertile patients who were not using contraception; pregnant or lactating patients; active infection; severe cardiopulmonary, neurologic, or metabolic disease; inadequate liver function (bilirubin $ 2.5 3 upper limit of normal) or renal function (creatinine $ 150 mmol/L or $ 2.0 mg/dL) unless they were a result of HL. Written informed consent per the local ethics committee was mandatory before enrollment. The study was conducted according to the Declaration of Helsinki.
Treatment
Random assignments were stratified by institution and IPS (3 v $ 4). The standard treatment was eight cycles of ABVD (ABVD 8 ) given every 4 weeks. The experimental treatment was four cycles of BEACOPP escalated followed by four cycles of BEACOPP baseline (BEACOPP 4+4 ) given every 3 weeks. Prophylactic granulocyte colony-stimulating factor was mandatory with BEACOPP escalated . Planned regimens are listed in Appendix Table A1 (online only).
Assessments and End Points
Disease assessment was planned after cycles 4, 6, and 8 by using clinical and computed tomography examinations according to the Response Evaluation Criteria in Solid Tumors (RECIST) for HL.
28
The central study coordinators (CSCs) blindly reviewed the responses of the local investigator (LI). An extension of the definition for CRu (as defined in the HD12 trial) was used for central review: patients who, on the basis of disease status evaluation at 4 to 6 weeks after treatment completion, were in partial response without additional treatment and progression of disease within 6 months.
15 EFS was the primary end point, defined as the time from random assignment to early discontinuation of protocol treatment and no CR or CRu after eight cycles of chemotherapy, relapse, progression, or death. Secondary end points were CR or CRu, disease-free survival (DFS) in patients with CR, OS, quality of life, second malignancies, and cost effectiveness. As a result of the composite nature of the primary end point (including both treatment efficacy and feasibility), PFS was defined as time from random assignment to progression, relapse, or death and was also analyzed after the study was closed. Toxicities were graded according to Common Toxicity Criteria version 2.0.
Statistical Design and Planned Analysis
The study was designed to detect a 10% increase in the 3-year EFS rate from 70% (ABVD 8 ) to 80% (BEACOPP 4+4 ; hazard ratio [HR], 0.62) by using a two-sided log-rank test with type I error of 0.05. With one interim analysis, 152 events were required to yield a power of 80% with 550 patients randomly assigned over 5.5 years and observed for 8 months after last random assignment. An interim analysis of EFS was planned after 50 events to stop the trial in case of superiority of the experimental arm. An alpha-spending function with a boundary parameter equal to 0.2 based on the Wang-Tsiatis method was used as a compromise between the O'BrienFleming and the Pocock approaches. 29 The Independent Data Monitoring Committee was to be consulted if the lower limit of the 95% CI for the death-as-a-result-of-toxicity rate was $ 3% in any arm. All randomly assigned patients were to be included in the analysis of efficacy end points per intention to treat. The Kaplan-Meier method was used to analyze timeto-event end points, and the log-rank test was used to compare the two arms. 30, 31 All inferential tests were performed at the two-sided a = .05 level, and estimates were provided with their 95% CIs. Adverse events (AEs) were analyzed for all patients who started protocol therapy. The worst grade for each Common Toxicity Criteria toxicity item recorded during the entire treatment period was tabulated. For the most frequent events, the proportions of grade 4 hematologic toxicities and of grade 3 or 4 nonhematologic toxicities were computed with 95% CIs. Relative dose intensity (RDI) was the ratio (%) of the average 1-day dose administered or planned during the treatment period. This article is based on data for 549 patients with 233 events for the primary end point up to the clinical cutoff date of November 19, 2010, 2 months after all patients stopped protocol treatment (Fig 1, CONSORT diagram) . Median follow-up was 3.6 years.
RESULTS
Between October 2002 and January 2010, 550 patients were randomly assigned. One patient who lacked informed consent was not included, leaving 275 (ABVD 8 ) and 274 (BEACOPP4 +4 ) intention-to-treat patients. Three (ABVD 8 ) and five (BEACOPP 4+4 ) patients who did not start treatment were excluded from safety analyses (Fig 1) . Eighteen patients (3%), nine in each arm, among whom 15 started treatment, were ineligible because of the absence of bidimensionally measurable target lesion (3), concomitant active diseases (2), IPS , 3 (2), age older than 60 years (1), inappropriate stage (4), histology (4), prior treatment (1), and inadequate organ function (1). There were 531 eligible patients, 266 in the ABVD 8 arm and 265 in the BEACOPP 4+4 arm (per protocol population). No data were available at the time of database lock for two BEACOPP 4+4 patients (Fig 1) .
Patient Characteristics
Baseline characteristics are provided in Table 1 and include stage IV disease, 74%; WHO PS 0 to 1, 82%; and "B" symptoms, 81%. Median age was 35 years, 75% were males, and IPS was $ 4 in 59% of patients. Baseline characteristics were balanced across the two groups.
Flow of Patients and Adherence to Protocol Treatment
In the ABVD 8 arm, three patients did not start treatment, 229 (84%) completed treatment, and 43 discontinued treatment, compared with the BEACOPP 4+4 arm in which five patients did not start treatment, 218 (81%) completed treatment, and 49 discontinued treatment. Reasons for treatment discontinuation in the ABVD 8 and BEACOPP 4+4 arms were progressive disease (eight v one), inability to achieve partial response after cycle 4 or CRu after cycle 6 (nine v 11), toxicity (seven v 24), patient refusal (seven v six), and death not as a result of HL (two v two), respectively (Fig 1) .
Main protocol treatment violations were the absence of fully documented restaging at cycle 6 contrary to protocol requirements: 54% (ABVD 8 ) and 48% (BEACOPP 4+4 ) of the patients continued chemotherapy beyond cycle 6 without restaging. Incorrect response assessment was observed for 5.1% and 3.6% of the patients in the ABVD 8 and BEACOPP 4+4 arms, respectively. RDI for ABVD 8 was 97.5% for doxorubicin, 92.6% for bleomycin, 95.7% for vinblastine, and 97.0% for dacarbazine. RDI for the four cycles of BEACOPP escalated was 100.9% for doxorubicin, 99.7% for cyclophosphamide, 96.3% for etoposide, and 99.6% for procarbazine; vincristine was the only drug with an RDI below 90%. Treatment was delayed, reduced, or both less often in the ABVD 8 arm than in the BEACOPP 4+4 arm (16.7% v 30.6% of cycles), usually from hematologic toxicity.
Response
A total of 227 patients (83%; 95% CI, 78% to 87%) achieved a CR or CRu, which was the same in both arms after centralized review, a higher number than that from the LI. According to the LI, CR was achieved by 202 patients (73.5%; 95% CI, 68.2% to 78.7%) in the ABVD 8 arm and by 189 patients (69.0%; 95% CI, 63.5% to 74.5%) in the BEACOPP 4+4 arm.
EFS (primary end point)
EFS at 4 years was 63.7% in the ABVD 8 arm and 69.3% in the BEACOPP 4+4 arm (HR, 0.86; 95% CI, 0.64 to 1.15; P = .313 by Abbreviations: ABVD 8 , doxorubicin, bleomycin, vinblastine, and dacarbazine (eight cycles); BEACOPP 4+4 , bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (four cycles of BEACOPP escalated followed by four cycles of BEACOPP baseline ; HL, Hodgkin lymphoma. centralized review; Table 2 and Fig 2) . The events that defined EFS were premature discontinuation (10.5% v 13.9%), no CR or CRu at cycle 8 (9.1% v 4.7%), progression or relapse (12.7% v 7.7%), and death (3.3% v 3.3%), respectively. In the BEACOPP 4+4 arm, more patients ended protocol treatment prematurely as a result of immediate hematologic and infectious complications, including septic shock (one [ABVD 8 ] v 18 [BEACOPP 4+4 ]). Indeed, compared with the ABVD 8 arm, grade 4 hematologic toxicity was more frequent in the BEACOPP 4+4 arm for neutropenia (31.6% v 64.7%), febrile neutropenia (5.9% v 33.8%), severe AEs, and severe adverse reactions, which were sevenfold more frequent (101 v 708). Respiratory-related treatment discontinuations were more frequent and severe in the ABVD 8 arm (7 v 5), including two deaths as a result of toxicity. An amendment for additional lung function tests prevented additional respiratory severe AEs. No difference for EFS was observed per LI in either arm (Appendix Table A2 [online only] and Appendix Fig A1 [online only] ).
DFS in CR and CRu Patients
DFS rates in CR and CRu patients at 4 years were 85.8% in the ABVD 8 arm and 91.0% in the BEACOPP 4+4 arm (HR, 0.59; 95% CI, 0.33 to 1.06; P = .076; by centralized review: Table 2 and Fig 3) .
PFS
PFS rates at 4 years were 72.8% in the ABVD 8 arm and 83.4% in the BEACOPP 4+4 arm (HR, 0.58; 95% CI, 0.39 to 0.85; P = .005 by centralized review [ Table 2 and Appendix Fig A2, online only] and by LI [Appendix Table A2 and Appendix Fig A2] ).
OS and Causes of Death
OS rates at 4 years were 86.7% in the ABVD 8 arm and 90.3% in the BEACOPP 4+4 arm (HR, 0.71; 95% CI, 0.42 to 1.21; P = .208; Table 2 and Fig 4) . We observed 56 deaths (Tables 2 and 3) : 33 (12.0%) in the ABVD 8 arm and 23 (8.4%) in the BEACOPP 4+4 arm. The main causes were HL (15 and seven patients) and toxicity (nine and six patients), respectively (Table 3 ). Only one death as a result of HL (BEACOPP 4+4 ) occurred early (ie, within 3 months of the end of treatment). There were 11 early deaths as a result of toxicity (six in the ABVD 8 arm and five in the BEACOPP 4+4 arm), including five (two and three) on treatment as a result of bleomycin-induced acute respiratory distress syndrome, acute hepatitis (ABVD 8 [one in each arm]), septic shock during aplasia, including one case of enterocolitis (BEACOPP 4+4 [three]). Death as a result of a secondary malignancy occurred in two and four patients, respectively.
AEs and Toxicity During Treatment
Grade 4 hematologic toxicities in the ABVD 8 and BEACOPP 4+4 arms were a result of febrile neutropenia in 0.0% and 6.3%, leucopenia in 4.8% and 70.6%, granulocytopenia in 31.6% and 64.7%, and thrombocytopenia in 0% and 7.8% of the patients, respectively. Main nonhematologic toxicities (grade 3 to 4 in $ 5% of patients) were cardiovascular other than edema, hypertension, or hypotension (4.8% and 7.4%); fatigue (2.6% and 10.4%); GI other than anorexia, constipation, diarrhea, nausea, or vomiting (1.8% and 9.7%); infection in non-neutropenic patients (4.4% and 9.7%); neurologic other than dizziness or neuropathy (2.6% and 5.2%); and pulmonary other than cough, dyspnea, or pleural effusion (4.0% and 7.1%). Deaths in the ABVD 8 and BEACOPP 4+4 arms that were not a result of HL were, respectively, bleomycin-induced pulmonary toxicity (six and zero), septic shock or severe intercurrent infection (four and eight), liver failure (one and two), cardiomyopathy (two and one), and death after a second tumor (two and four), including non-Hodgkin lymphoma (NHL; two and one), bronchogenic and unknown primary carcinoma (zero and two), and acute monoblastic leukemia (zero and one).
Late AEs and Second Malignancies
Second malignancies were observed in eight patients in the ABVD 8 arm (two lung, three NHL, two myeloproliferative diseases, one other) and in 10 patients in the BEACOPP 4+4 arm (one lung, two NHL, four myeloproliferative disease, three other). Cumulative incidence rates (Appendix Fig A3, online only) did not differ significantly (3.4% and 4.7% at 4 years, respectively).
DISCUSSION
This randomized phase III trial compared ABVD 8 and BEACOPP 4+4 to assess chemotherapy dose density and dose intensity in the highest-risk patients (IPS $ 3) with stage III or IV HL (n = 550). Patients with poor-prognosis stage II disease (13% of the advanced-stage HL series) who were potentially curable with less treatment, were excluded. Our patient population accounted for 42%, 43%, 54%, and 59% of the advanced-stage HL population of the initial IPS project, HD9, EORTC 20804, and Groupe d'Etude des Lymphomes de l'Adulte H89 studies, respectively. 18, 19, 32, 33 The corresponding FFTF rates were 55%, 64%, and 84% at 3 years and 72% at 5 years, respectively, although OS rates were 78%, 86%, and 89% at 3 years and 80% at 5 years, a suboptimal result. The EORTC 20012 Intergroup study investigated whether patients age 60 years or younger with stages III to IV HL at the highest-risk IPS ($ 3) would most benefit from dosedense and dose-intense treatment, in keeping with the Kairos hypothesis. 16 EFS was chosen as the main end point to account for treatment efficacy and feasibility. Positron emission tomography imaging, not standard when the trial started, was excluded from the initial response assessment plan. To secure patient management, response evaluations were scheduled after cycles 4 and 6 in both arms. However, protocol time point evaluations were often omitted by the LI (primary analysis), particularly after cycle 6. Nevertheless, a retrospective central evaluation of responses (sensitivity analysis) was performed in all cases by the CSC (M.D., N.M., P.C.). No statistically significant difference was observed in EFS between the ABVD 8 and BEACOPP 4+4 arms by either local or central assessment.
Despite similar CR and EFS rates, causes of treatment failure diverged between the ABVD 8 and BEACOPP 4+4 arms. More patients progressed or relapsed in the ABVD 8 arm than in the BEACOPP 4+4 arm; however, the resulting DFS and PFS were much closer than anticipated from the results of the HD9 trial. DFS was a better parameter for expressing dose-response, as reported in the Standardized Response Criteria (revision 2007). The same observation applies to PFS. ABVD 8 turned out to be more effective than COPP/ABVD, contrary to the prediction of the equivalent effective doses model, simply because "doxorubicin is confirmed as most important drug in [HL] ," as acknowledged by Hasenclever himself. 13 Central reviewers noted that many deaths as a result of toxicity could have been avoided considering the poor initial condition of patients: indeed, numbers were similar in both arms (six v five patients; 2% overall), in keeping with observations of the German Hodgkin Study Group. as in the BEACOPP 4+4 arm of the HD12 trial for patients with standard-risk stages II, III, or IV disease who received radiotherapy.
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Some questions were not answered. Late morbidity will be reported later, hopefully decreased by the omission of irradiation. 35, 36 However, BEACOPP 4+4 induced 3.5-fold more secondary hematologic malignancies than other regimens. 37 Furthermore, in the HD2000 randomized trial, second malignancy risk-mostly solid tumors-at 10 years was 6.7 for BEACOPP 4+4 versus 0.9 for ABVD (P = .027). 38 Although ABVD is known to preserve fertility, BEACOPP is associated with testicular and ovarian damage. [39] [40] [41] [42] [43] This is a significant drawback in a young population (median age, 35 years; 67% of patients were younger than age 44 years). Feasibility and the results of stem-cell harvest for salvage therapy for our progressing or relapsing patients after ABVD 8 and BEACOPP 4+4 will be reported.
The large EORTC 20012 Intergroup trial compared ABVD 8 and BEACOPP 4+4 administered with excellent compliance in patients in the highest-risk group of advanced-stage HL. As compared with ABVD, BEACOPP 4+4 produced an identical CR/ CRu rate (82%) and no significant increase in 4-year EFS and OS. The marginal effect seen on DFS in favor of BEACOPP 4+4 (P = .001 [per LI]; P = .076 [per CSC]) did not translate into a difference in OS. A higher PFS for BEACOPP 4+4 (centralized review) also did not translate into higher OS, contrary to the result of the companion Lymphoma Study Association trial in patients with IPS 0 to 2. 44 One explanation may be a better efficacy of salvage therapy after ABVD 8 . Another explanation might be a poorer tolerance of BEACOPP 4+4 in the population of patients with more severe initial characteristics than in the other studies: age 35 versus 28 years; sex ratio of males to females, 3:1 versus 1:1; WHO PS of 1 or higher, 66% versus 36%; stage IV, 74% versus 57%; and B symptoms, 81% versus 54%. 45, 46 Our results confirm the results of two studies that randomly assigned patients with advanced-stage HL to ABVD or BEACOPP 4+4 , which resulted in identical OS, with fewer BEACOPP 4+4 patients requiring salvage therapy.
24,25 The disappointing yield from dose increment in the high-risk group, the severe early and late morbidities, and associated costs, all raise questions about the benefits of BEACOPP. Pooling the results of the three randomized studies that compared ABVD and BEACOPP 4+4 (manuscript in preparation) should reinforce their similar conclusions, assess potential differences, and may identify a group of patients that benefit from initial increment of dose intensity and dose density while minimizing immediate and late toxicities. Meanwhile, new agents should be tested with both regimens.
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